Johnson & Johnson reported strong Q4 and full-year results, exceeding expectations with solid sales growth and a 10.4% increase in adjusted EPS. Management expressed confidence in their future outlook, highlighted cost-saving measures, and provided positive guidance for 2008, indicating continued earnings growth. Despite some challenges in the pharmaceutical segment, the overall optimistic tone and strategic initiatives suggest a positive short-term impact on the stock price.

[1]